Kairos Pharma Secures Department of Defense Grant for Lung Cancer Biomarker Research
Kairos Pharma has received a Department of Defense grant to advance research on lung cancer biomarkers, furthering its innovative approach to targeting drug resistance in cancer treatments. The company is progressing clinical trials for its lead candidates ENV105 and KROS101 with promising potential in oncology.
Kairos Pharma Ltd., a clinical-stage biopharmaceutical company, has secured a Department of Defense grant to support its ongoing lung cancer biomarker research. The company is currently advancing two critical clinical trials for its lead candidate ENV105, targeting prostate and EGFR-dependent non-small cell lung cancers.
The company expects to release safety and interim efficacy results for these trials in the second quarter of 2025. Additionally, Kairos is developing KROS101, an immune response modulator, with recent data presentations at key oncology conferences highlighting its potential therapeutic applications.
ENV105, the company's primary candidate, represents a novel approach to cancer treatment by targeting CD105, a protein identified as a key driver of treatment resistance. By addressing the mechanisms that lead to drug resistance and disease relapse, Kairos aims to restore the effectiveness of standard cancer therapies across multiple cancer types.
The non-dilutive government grant underscores the potential significance of Kairos Pharma's research. With an expanding trial network and analyst coverage from firms like EF Hutton and HC Wainwright, the company appears well-positioned to advance its oncology therapeutics platform.
The research has significant implications for cancer treatment, potentially offering new strategies to combat drug resistance and improve patient outcomes in challenging cancer types such as prostate and lung cancer.